Today Stories

AstraZeneca has entered into an exclusive license agreement with CSPC Pharmaceutical Group Ltd (CSPC) to advance the development of an early stage, novel small molecule Lipoprotein (a) (Lp(a)) disruptor that has the potential to offer additional benefits for patients with dyslipidaemia. This asset further strengthens the company’s cardiovascular portfolio to help address the major risk factors driving chronic cardiovascular disease.   Under the terms of the agreement, AstraZeneca will receive access to CSPC’s pre-clinical candidate small molecule, YS2302018, an oral Lp(a) disruptor, with the aim of developing this as a novel lipid-lowering therapy with potential in a range of cardiovascular disease indications alone or in combination, including with the oral small molecule PCSK9 inhibito…

Company Launches Accelerator™ Drug Development, 360° Contract Development and Manufacturing Organization (CDMO) and Contract Research Organization (CRO) Services that highlight advanced capabilities to help pharmaceutical and biotech customers solve global health challenges with new medicines and vaccines MILAN--(BUSINESS WIRE)-- Thermo Fisher Scientific Inc., the world leader in serving science, will showcase its latest innovations enabling the molecule-to-medicine journey and host a series of sessions that feature industry developments during CPHI Milan 2024, Oct. 8-10, in Milan, Italy. Leaders and experts from the company will be present at conference booth #7B18 to discuss how Thermo Fisher is supporting biotechnology and pharmaceutical companies across indications, modalities, sizes a…

mAbxience, a Fresenius Kabi majority-owned group, and Teva Pharmaceuticals International have entered a second global licensing agreement for an anti PD-1 biosimilar candidate currently in development for the treatment of multiple oncology indications. The agreement covers global markets, including in Europe and the United States. Fresenius Kabi, an operating company of Fresenius, continues to strengthen its biopharma business and strategic network through this new agreement, which builds on the solid foundation of the initial partnership with Teva. This directly underscores the companies’ mutual goal to provide cost-effective, high-quality biosimilar treatments that address critical unmet needs in oncology care. By leveraging expertise and resources, the collaboration continues to drive i…

The Almac Group has today announced an £11m investment and the creation of over 100 new jobs to expand its global analytical services capabilities. Over the past 18 months, Almac Sciences and Almac Pharma Services have jointly made this significant investment to expand their existing analytical laboratories, technology and resource to meet ongoing global demand. Almac employs over 700 highly skilled analysts working in regulatory approved GMP laboratories across five locations in Craigavon, UK; Charnwood, UK; Souderton, Pennsylvania; Athlone, Ireland and Dundalk, Ireland.  Construction of new laboratory space at the company’s global Headquarters in Craigavon considerably increases overall capacity, while additional upgrades and development of existing labs across all sites mean Almac will…

Chiesi Group is making a strategic investment of €400 million to establish its new Biotech Center of Excellence in Parma. The Center is designed to integrate the entire supply chain, enhancing innovation and production, while its seamless research-production integration will accelerate product development and autonomous production capacity. Chiesi’s strategy aligns with EU priorities on innovation, security, and private R&D investment. Parma (Italy), 30th September 2024 - Today, Chiesi Group, an international biopharmaceutical company focused on research, celebrates the operational launch of its Biotech Center of Excellence. This state-of-the-art facility is dedicated to developing and producing monoclonal antibodies, enzymes, and other proteins. This facility is anticipated to be ou…

Global investigative sites recognize Parexel’s commitment to strong site relationships and patients DURHAM, N.C., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Parexel, one of the world’s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services, today announced it has been awarded the 2024 Society for Clinical Research Sites (SCRS) Eagle Award in the CRO category for the second consecutive year. This prestigious award, presented at the annual SCRS Global Site Solutions Summit held Sept. 27-29 in Hollywood, Fla., underscores Parexel’s dedication to fostering strong partnerships with investigative sites and advancing patient-guided clinical research. "This recognition reaffirms our commitment to collaborating with sites, which is crucial for…

Boehringer Ingelheim has entered a partnership with the NCD Alliance, a network dedicated to shaping a world in which everyone can live a healthy and productive life, free from the preventable suffering, stigma, disability, and death caused by non-communicable diseases (NCDs). The start of the partnership was announced alongside the United Nations Global Assembly in New York. NCDs are a major global health issue. These diseases, which are not transmitted from person to person, cause 41 million deaths each year, accounting for 74% of all deaths worldwide.  With at least one in three people living with a NCD and half the world's population lacking essential health services, many are not receiving the care they need. Within the broad category of NCDs, there are specific types known as Card…

Provides patients with certain chronic lung conditions and retained secretions added comfort, user-friendly touch screen and unique garment design options Developed in consultation with clinicians and patients for an enhanced user experience The Vest uses High Frequency Chest Wall Oscillation therapy, a therapy for which Hillrom, now part of Baxter, has been a pioneer and industry leader BOSTON, Mass. - 2024-09-26 Baxter International Inc. (NYSE:BAX), a leading global medtech company, today unveiled its next generation airway clearance system, The Vest Advanced Pulmonary Experience (APX) System, at the North American Cystic Fibrosis Conference. The Vest APX System supports daily therapy for adults and children with certain chronic lung conditions and retained secretions. The system…

Inauguration of Angelika Amon research building in Vienna  Sustainable research building at a cost of EUR 60 million offers modern office and laboratory space Over the past five years, Boehringer’s capital investments reached EUR 6.0 billion Boehringer Ingelheim is one of the world's leading research-oriented pharmaceutical companies. The clinical pipeline is constantly being further developed, and Boehringer Ingelheim expects new approvals also in oncology in the coming years.  An important investment in the future is the new Angelika Amon Research Building, opened on September 25, in the presence of guests from politics and science. The modern and sustainable building offers ideal conditions for researchers on 11 floors, where 150 people work on promising therapeutic approaches agai…

New TAGS (Temperature-Activated Generation of Signal) technology enables up to 15 targets to be detected simultaneously in a single patient sample on the high throughput molecular diagnostic analysers cobas 5800, 6800 and 8800. TAGS has the potential to revolutionise testing for other infectious diseases in the future, by bringing high throughput customised syndromic panel testing to the routine clinical laboratory. The first TAGS-based test to be made available, the cobas Respiratory flex, offers fast, efficient detection of up to 12 of the most common respiratory viruses with the flexibility for targeted testing, expediting accurate diagnosis, optimising antimicrobial use and saving time in the lab. Basel, 24 September 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the launc…

New TAGS (Temperature-Activated Generation of Signal) technology enables up to 15 targets to be detected simultaneously in a single patient sample on the high throughput molecular diagnostic analysers cobas 5800, 6800 and 8800. TAGS has the potential to revolutionise testing for other infectious diseases in the future, by bringing high throughput customised syndromic panel testing to the routine clinical laboratory. The first TAGS-based test to be made available, the cobas Respiratory flex, offers fast, efficient detection of up to 12 of the most common respiratory viruses with the flexibility for targeted testing, expediting accurate diagnosis, optimising antimicrobial use and saving time in the lab. Basel, 24 September 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the launc…

J.POD® Toulouse, France (EU) brings disruptive, scalable continuous biologics manufacturing technology to the region Just – Evotec Biologics’ J.POD® technology offers a paradigm shift in biomanufacturing with cost-effective and flexible clinical and commercial supply solutions Hamburg, Germany, and Toulouse, France, 20 September 2024:Just – Evotec Biologics, the biologics segment of Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO), today celebrated the Grand Opening of its J.POD® biologics development and manufacturing facility located on Evotec’s Campus Curie in Toulouse, France. The J.POD® facility in Toulouse, the second of its kind and the first in Europe, utilizes Just – Evotec Biologics’ adaptable J.POD® technology to provide essential clini…

Award Recognizes Leadership in AI Regulatory and Quality Solutions for Healthcare RESEARCH TRIANGLE PARK, N.C. – IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced that Frost & Sullivan, a leading independent research and consulting firm, has awarded IQVIA with the 2024 Global Customer Value Leadership Award for excellence in the global artificial intelligence (AI) quality and regulatory solutions space for the healthcare industry.  Frost & Sullivan’s annual Customer Value Leadership Award recognizes the company that offers products or services that customers find superior in overall price, performance and quality. IQVIA was awarded this recognition for its Enterprise…

Stryker (NYSE: SYK) announced that it has completed the previously announced acquisition of care.ai, a privately held company specializing in delivering AI-assisted virtual care workflows, smart room technology and ambient intelligence solutions. “We welcome the care.ai team to Stryker and look forward to working together to accelerate our digital vision to provide customers with real-time, smart and connected decision-making tools that can enhance the lives of caregivers and their patients,” stated Andy Pierce, Group President, MedSurg and Neurotechnology, Stryker. The acquisition will strengthen Stryker’s growing healthcare IT offering and wirelessly connected medical device portfolio. About StrykerStryker is a global leader in medical technologies and, together with its custom…

The new research team led by Dr. Stefanie Bärthel will work on developing next-generation immunotherapies by leveraging the antitumor effects of neutrophils. Heidelberg, September 17, 2024. BioMed X, a German biomedical research institute, announced the start of a new research team at the BioMed X Institute in Heidelberg, Germany, the institute’s first joint research project with the Japanese company Ono Pharmaceutical Co., Ltd. The scope of this project is to investigate the antitumor effects of neutrophils to develop novel next-generation immunotherapies. The presence of neutrophils in solid tumors has been well-documented, albeit their role in the tumor microenvironment seems paradoxical according to the current data. “We know far more about T cells in the context of immunotherapy tha…

Enhances Labcorp's laboratory services network and expands access to its clinical services  BURLINGTON, N.C. and MIAMI, Sept. 16, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and OPKO Health, Inc. (Nasdaq: OPK), a multinational biopharmaceutical and diagnostics company, announced today the completion of Labcorp's acquisition of select assets of BioReference Health, a wholly owned subsidiary of OPKO Health. The transaction is expected to provide patients, physicians and customers with greater access to Labcorp's comprehensive, high-quality laboratory services, scientific expertise and expanded testing capabilities in key regions across the country. The acquisition includes BioReference Health's laboratory testing businesses fo…

OCREVUS ZUNOVO™ has the potential to expand treatment options to centres without IV infrastructure or with IV constraints, like at a doctor's office This approval is backed by a decade of proven safety and efficacy data of Ocrevus® IV, with over 350,000 people treated globally OCREVUS ZUNOVO™ offers people with multiple sclerosis (MS) more options to access treatment based on their individual needs Basel, 16 September 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the United States Food and Drug Administration (U.S. FDA) has approved OCREVUS ZUNOVO™ (ocrelizumab & hyaluronidase-ocsq) for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). OCREVUS ZUNOVO is the first and only twice-a-year, healthcare professional (HCP)-admin…

Company ups manufacturing investment in Limerick by $1 billion; unveils new $800 million Kinsale facility New investment will enhance global medicine production, benefiting millions of patients worldwide INDIANAPOLIS, Sept. 12, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced a $1 billion expansion of its Limerick, Ireland, manufacturing site to increase production of biologic active ingredients, including those for its recently approved treatment for early symptomatic Alzheimer's disease. The company also unveiled its new $800 million facility expansion in Kinsale, Ireland, which began making medicines last year to meet demand for Lilly's latest diabetes and obesity treatments. This additional investment is part of the most ambitious manufacturing expansion agenda…

-- Gilead and Genesis Will Leverage the GEMS AI Platform to Generate and Jointly Optimize Molecules Against Selected Targets -- -- Gilead Receives Exclusive Rights to Develop and Commercialize Products from the Collaboration -- FOSTER CITY, Calif. & BURLINGAME, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) and Genesis Therapeutics, Inc. announced today that the companies have entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets. Genesis is pioneering generative and predictive artificial intelligence (AI) technologies to help create therapeutics for challenging targets. This collaboration will deploy Genesis’ field-leading AI platform, GEMS (Genesis Exploration of Molecular Space), to assist in generati…

Switzerland’s most innovative research and development center underscores Roche’s long-term investment in scientific advancement to meet patient needs The new center will simplify and increase collaboration thereby accelerating scientific innovation Guy Parmelin, Federal Counsel and Head of the Federal Department of Economic Affairs, Education and Research (EAER) will attend the center’s inauguration Basel, 10 September 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the opening of its new Pharma Research and Early Development (pRED) Center at its global headquarters in Basel, Switzerland. Equipped with cutting-edge technologies and housing around 1,000 state-of-the-art laboratory and office workplaces, the new center brings together teams of scientists and researchers to accel…